“Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s273. doi:10.25251/skin.7.supp.273.